Navigation Links
Benefit of novel drug in breast cancer seen in blood within weeks
Date:11/13/2011

SAN FRANCISCO Clinical benefit from use of a novel histone deacetylase inhibitor drug may be determined by examining blood cells days after a patient receives treatment. The drug, entinostat, is the first histone deacetylase inhibitor successfully tested in a randomized, placebo-controlled study in metastatic breast cancer and is the first to show that clinical outcome can be predicted shortly after administration.

The findings, reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011, represent an advance in the goal to offer patients only those therapies that will help treat cancer effectively, the researchers said.

"The ability to have a marker of benefit within the first several weeks of using this drug represents an exciting advance in personalized medicine," said lead researcher Peter Ordentlich, Ph.D., executive director of translational science and a founder of Syndax Pharmaceuticals Inc. in Waltham, Mass. Syndax Pharmaceuticals developed entinostat, an oral small-molecule drug that inhibits enzymes that alter the packaging of DNA inside the nucleus, which controls gene expression.

"The goal of entinostat in breast cancer is to extend the benefit of hormone therapy and delay the time that patients will need to use chemotherapy," said Ordentlich. More than 160,000 women are diagnosed each year with estrogen receptor (ER)-positive invasive breast cancer, and many are treated with agents that block the hormone. But most women become resistant to these therapies, and entinostat, combined with antihormone agents, is meant to extend their benefit, he said.

To test that strategy in ER-positive metastatic breast cancer, Syndax Pharmaceuticals conducted ENCORE-301, a randomized, placebo-controlled, phase 2 study (n=130) testing the use of exemestane, an aromatase inhibitor, with either entinostat or placebo.

Results of the clinical trial, released in
'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Advanced Medical Care for At-Risk Newborns Nets Economic Benefits
2. Report provides new analysis of carbon accounting, biomass use, and climate benefits
3. Awareness and labeling initiatives can benefit inland fisheries
4. Obese adolescents benefit from high-dose vitamin D supplements
5. Vitamin D study suggests no mortality benefit for older women
6. Fatty acids involved in python heart growth could benefit diseased human heart
7. Turning slash piles into soil benefit
8. Commercial dry petfood has significant benefits for oral health in cats and dogs
9. Health benefits of broccoli require the whole food, not supplements
10. Everest expedition suggests nitric oxide benefits for intensive care patients
11. New study of Glovers Reef challenges whether corals will benefit from Marine Reserves protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Putnam Valley, NY. (June 26 , 2012) Researchers ... transplanting two varieties of stem cells into mouse cochlea ... cells and mouse embryonic stem (ES) cells demonstrate similar ... risk of tumor growth associated with transplanting iPS cells ...
... NEVERS, France, June 26, 2012 Polar ( ... assessment technology, together with LOOK , the inventor and ... of the first clipless cycling pedals to measure cycling power ... left/right balance and power output, and send the data directly ...
... discovered a new flu-fighting role for a well-known component ... cellular biology in the UGA Franklin College of Arts ... cell-signaling protein known as IL-15 to mice infected with ... times. "We gave the IL-15 intranasally and ...
Cached Biology News:Stem cell transplantation into mouse cochlea may impact future hearing loss therapies 2Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 2Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 3Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 4UGA study reveals flu-fighting role for well-known immune component 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Aug. 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ... company,focused on commercializing proprietary product candidates for ... announced that the U.S. Food and,Drug Administration ... ANX-510,or CoFactor(R) injection, which is currently being ...
... Drug Application in the Fourth ... ... positive results from a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal ... chronic non-cancer pain,conditions. The study achieved statistical significance on the primary,endpoint. Results ...
... Presentations on the Topic of Drug Repurposing and ... Indian Clinical ... Inc., an,oncology-focused, clinical-stage biopharmaceutical company, announced today,that Chief Executive Officer, ... present at the 234th American Chemical,Society National Meeting on Sunday, ...
Cached Biology Technology:ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
...
Biology Products: